Erasca, Inc.
ERAS
Rangering i aksjer
#3403
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Aksjekurs
$14.62
Markedsverdi
$5.11B
Endring (1 dag)
7.34%
Endring (1 år)
494.31%
Land
US
Handel Erasca, Inc. (ERAS)
Kategori
Healthcare
P/B-forhold for Erasca, Inc. (ERAS)
P/B-forhold per October 2026 TTM: 12.65
Ifølge Erasca, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 12.65. Ved slutten av 2023 hadde selskapet et P/B-forhold på 1.01.
P/B-historikk for Erasca, Inc. fra 2019 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 12.65 | 809.88% |
| 2024 | 1.39 | 37.19% |
| 2023 | 1.01 | -20.90% |
| 2022 | 1.28 | -68.58% |
| 2021 | 4.06 | -122.34% |
| 2020 | -18.19 | -88.07% |
| 2019 | -152.41 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -50.57% |
US
|
|
| 13.2547 | 4.80% |
US
|
|
| 4.208 | -66.73% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -51.12% |
NL
|
